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Abstract
Age-related changes in the liver sinusoidal endothelium, particularly the reduction in fenestrations, contribute to insulin resistance in old 
age. Metformin impacts on the aging process and improves insulin resistance. Therefore, the effects of metformin on the liver sinusoidal 
endothelium were studied. Metformin increased fenestrations in liver sinusoidal endothelial cells isolated from both young and old mice. Mice 
administered metformin in the diet for 12 months had increased fenestrations and this was associated with lower insulin levels. The effect of 
metformin on fenestrations was blocked by inhibitors of AMP-activated protein kinase (AMPK), endothelial nitric oxide synthase, and myosin 
light chain kinase phosphorylation. Metformin led to increased transgelin expression and structural changes in the actin cytoskeleton but had 
no effect on lactate production. Metformin also generated fenestration-like structures in SK-Hep1 cells, a liver endothelial cell line, and this 
was associated with increased ATP, cGMP, and mitochondrial activity. In conclusion, metformin ameliorates age-related changes in the liver 
sinusoidal endothelial cell via AMPK and endothelial nitric oxide pathways, which might promote insulin sensitivity in the liver, particularly 
in old age.
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Metformin is prescribed for type 2 diabetes mellitus and delays 
aging via effects on nutrient sensing pathways (1–3). Its mode of 
action is unclear but involves activation of AMP-activated protein 
kinase (AMPK) secondary to inhibition of mitochondrial respira-
tory activity (4). The primary target organ of metformin is the liver 
(5,6) where metformin downregulates protein synthesis (7), lipo-
genesis (8,9), and gluconeogenesis (10), and upregulates insulin 
signaling (8,11).
Aging is associated with a number of changes in liver function 
and structure, including hepatic insulin resistance (1,12–15). We 
found that old age leads to changes in the liver sinusoidal endothe-
lial cells (LSEC), which may contribute to hepatic insulin resistance. 
LSECs have a unique morphology including the presence of fenestra-
tions which are transcellular pores that facilitate the transfer of sub-
strates such as insulin between blood and hepatocytes. With old age, 
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endothelium, upregulation of endothelial markers, and perivascular 
deposition of collagen and basal lamina (15,16). These age-related 
changes, termed “pseudocapillarization,” impair the uptake of in-
sulin leading to hepatic insulin resistance and reduced clearance of 
insulin (14,15).
Here, we investigated the effects of metformin on fenestrations in 
old age, and mechanisms for the effects of metformin on LSECs. We 
also studied the molecular pathways promoted by metformin in and 




The study was approved by the Animal Welfare Committee of the 
Sydney Local Health District and was performed in accordance with 
the Australian Code of Practice for the care and use of animals for 
scientific research (AWC: 2016/009, 2018/010). All information pro-
vided accords with ARRIVE guidelines.
Reagents
Cell/tissue culture: collagenase (Type 1, cat no: 47D17410A, 
ProSciTech, Australia), RPMI-1640 (cat no: R0883, Sigma–
Aldrich, Australia), Percoll (cat no: P4937, Sigma–Aldrich), 
1,1-Dimethylbiguanide hydrochloride (metformin cat no: D150959, 
Sigma–Aldrich), Dulbecco’s modified Eagle medium (cat no: 
M8042, Sigma–Aldrich), penicillin–streptomycin (cat no: P4333, 
Sigma–Aldrich), fetal calf serum (cat no: F2442, Sigma–Aldrich), 
Dorsomorphin dihydrochloride (Compound C, cat no: ab144821, 
Abcam, Australia), Myosin Light Chain Kinase Inhibitor Peptide 18 
(cat no: 475981, Merck, Australia), Nω-Nitro-L-arginine methyl 
ester hydrochloride (cat no: N5751, Sigma–Aldrich). Assays were 
performed using In Vitro Toxicology Assay Kit, MTT based (cat 
no: TOX1-1KT, Sigma–Aldrich), cyclic guanosine monophosphate 
(cGMP) ELISA kit (cat no: 581021, Sapphire Bioscience, Australia), 
ATP bioluminescence assay kit (cat no: A22066, ThermoFisher, 
Australia), L-lactate assay kit (cat no: 700510, Sapphire Bioscience, 
Australia), and mouse insulin ELISA kit (cat no: 90080, Crystal 
Chem Inc, IL). Antibodies: p-AMPKα (Thr172, cat no: 2531, 
Cell signaling Technology, Australia), AMPKα (cat no: 2532, 
Australian Biosearch, Australia), anti-p-eNOS (Ser1177, cat no: 
9571, Genesearch, Australia), anti-eNOS (type 3, cat no: 610296, 
BD Bioscience, Australia), transgelin (anti-SM22 alpha antibody; cat 
no: ab14106, Abcam), Alexa Fluor 488 phalloidin (cat no: A12379, 
Thermo Fisher, Australia), Alexa Fluor 488 Goat anti-Rabbit (cat 
no: R-37116; Thermo Fisher), MitotrackerGreen (cat no: M7514, 
Thermo Fisher), and TMRE (cat no: T669, Thermo Fisher). Western 
blot reagents: loading buffer (cat no: B0007, Thermo Fisher), run-
ning buffer (cat no: B0001, Thermo Fisher), transfer buffer (cat no: 
BT00061, Thermo Fisher), Ponceau staining (cat no: P7170, Sigma–
Aldrich), PBS tablets (cat no: P4417, Sigma–Aldrich), and Tween-20 
(cat no: P1379, Sigma–Aldrich).
In Vitro Cell Culture Studies
Three to four (n = 3) and 18 (n = 3)-month-old male C57/Bl6 mice 
were obtained from the Animal Resource Centre in Perth, Western 
Australia; and housed at the ANZAC Research Institute (Concord 
Repatriation General Hospital, NSW, Australia). Mice were group 
housed, maintained on a 12-hour light/dark cycle, 20–25°C, 50%–
60% relative humidity and provided with bedding, ventilated caging 
systems, and enrichment as per the ARRIVE guidelines. The Mice 
were anesthetized with ketamine and xylazine (100 mg/kg; 10 mg/
kg). LSECs were isolated and cultured as described (17–19). In brief, 
livers were perfused with collagenase and parenchymal cells were re-
moved by a two-step Percoll gradient. Küpffer cells were removed by 
selective adherence to plastic. LSECs were then cultured (37°C, 5% 
CO2) in serum-free RPMI-1640 for 3.5 hours before use.
SK-Hep1 cells were obtained from the American Type Tissue 
Culture Collection (ATCC, Manassas, VA). Cells were cultured 
(37°C, 5% CO2) in Dulbecco’s modified Eagle medium supple-
mented with 10% fetal calf serum and penicillin–streptomycin. Cells 
were plated in flasks coated with (0.2 mg/mL) fibronectin.
LSECs and SK-Hep1 cells were incubated with metformin con-
centrations at 5, 10, 25, 50, and 100 µM in RPMI media for 30 min-
utes. These concentrations were based on previous studies (3,20,21).
The effects of metformin on fenestrations were evaluated using 
scanning electron microscopy (SEM). SEM was performed as pre-
vious described using a JEOL 6380 Scanning Electron Microscope 
(JEOL Ltd, Japan) (17–19). Images at 10,000× magnification were 
captured and analyzed for: (i) fenestration porosity (defined as the 
percentage of the cell membrane covered with fenestrations relative 
to the total cell surface, excluding the nucleus area), (ii) fenestration 
diameter, and (iii) fenestration frequency (defined at the number of 
fenestrations per 1 µm2 per total cell surface). Between 1,713 and 
3,278 fenestrations were counted per treatment group, per mouse 
(8–16 images per mouse, minimum 3 mice per treatment) by a ob-
server blinded to the age and treatment group. Fenestrations less 
than 30 nm and gaps more than 300 nm were excluded from ana-
lysis similarly to our previous publication (19).
The effects of metformin on transgelin and the actin cytoskel-
eton were evaluated using direct stochastic optical reconstruction 
microscopy (dSTORM). Paraformaldehyde-fixed cells were stained 
with either Alexa Flour phalloidin 488 (1:40, 20 minutes) or 
transgelin (1:100, 16 hours 4°C) followed by Alexa Fluor 488 Goat 
anti-Rabbit (1:1,000, 2 hours). dSTORM used a 488 nm excitation 
from diode-pumped lasers (Coherent Inc, California). Excitation was 
delivered via a 1.49NA 60× oil-immersion TIRF objective (Olympus 
Australia, Australia). Fluorescence was captured on an industrial 
CMOS camera (Imaging Development Systems GmbH, Germany). 
Data were collected for up to 40,000 images at 75 fps. Eight whole 
cell images were collected for each treatment dosage and processed 
using RapidSTORM open source software (22). Densitometry meas-
urements were performed using eight dSTORM images with data 
analysis performed using Image J software (National Institute of 
Heath, Maryland) similarly to our previous publication (19).
Potential mechanisms for the effects of metformin in vitro were 
explored using several methods. Isolated LSECs were pretreated 
with Peptide 18 (100 µM, 45 minutes) (23), Compound C (10 µM, 
20 minutes) (6) or N(ω)-nitro-L-arginine methyl ester (L-NAME) 
(3  mM, 30 minutes) (24) to inhibit phosphorylated myosin light 
chain kinase (MLCK), phosphorylated AMPK, and endothelial nitric 
oxide synthase (NOS), respectively. Mitochondrial membrane poten-
tial was measured using tetramethylrhodamine, ethyl ester (TMRE) 
(100 nM, 10 minutes), and MitotrackerGreen (250 nM, 15 minutes) 
and imaged with a Leica SP8 inverted scanning confocal microscope 
with Type F immersion oil (cat. no. 11513859) and images captured 
using LAS software (Leica Microsystems CMS, Wetzlar, Germany) 
(25,26). SK-Hep1 cell lines were used for cGMP, L-lactate, ATP, and 
MTT assays that were performed as described elsewhere (19,25). 
Western blots for p-AMPK, AMPK, p-eNOS, and NOS with actin 
and Ponceau controls performed as previously described (25,26).
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Figure 1. Effects of metformin on isolated young and old mice liver sinusoidal endothelial cells. (a) Representative scanning electron microscopy (SEM) images 
following metformin treatment in young and old mice. Scale bars show 1  µm. (b–d) Dose–response curves showing changes in fenestration porosity (b), 
diameter (c), and frequency (e) with increasing dosage of metformin. Solid gray line shows young mice data, black line shows is old mice data. Gray and blank 
dotted lines show the mean control (untreated) score. All data show the mean ± SD with the metformin concentration shown with a log 10 scale. Porosity is 
shown as the percentage area occupied by fenestrations relative to the total cell area excluding the nucleus, and frequency shows the number of fenestrations 
per 1 µm2. *, # indicates a p-value of < .05 compared to young (*) or old (#) control data. All statistics were performed using Kruskal–Wallis with post hoc 
Dunn’s test to compare between groups, n = 3 (biological replicates) for all groups. All data were collected using 1,988–3,278 (young) or 1,713–2,345 (old) 
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Figure 2. Effects of fenestrations and circulating insulin following 12 months 0.1% metformin diet. (a) Sample scanning electron microscopy images of in vivo 
liver sinusoidal endothelial cells from chow-fed 3-month (left) and 15-month (middle)-old mice. Panel of right shows a 15-month-old mouse fed 0.1% metformin 
for 12 months. Scale bar shows 1 µm. (b–d) Changes in fenestration porosity (b), diameter (c), and frequency (d) between chow fed young mice, old mice; and 
old mice fed metformin diet. All data show the mean ± SD. All data were collected using 749–1,571 fenestration raw data points (per mouse). Statistics were 
performed using Kruskal–Wallis with post hoc Dunn’s test to compare between groups, n = 4 (biological replicates) for all groups. *, # indicates a p-value of < .05 
compared to 3-month chow fed (*) or 15-month chow fed (#). Porosity is shown as the percentage area occupied by fenestrations relative to the total cell area, 
diameter is given in nm and frequency shows the number of fenestrations per 1 µm2. (e) Changes in fasting and fed blood insulin between chow fed young mice 
(3 months; white bars) old mice (15 months, gray bars) and metformin fed old mice (15 months, black bars). Insulin measures were performed using 10 µL of 
whole blood from fasted mice (5 hours.) and again following an oral bolus of 25% glucose solution. All data show the mean ± SD. Statistics were performed 
using Kruskal–Wallis with post hoc Dunn’s test to compare between groups, n = 4 for all groups. *, # indicates a p-value of < .05 compared to 3-month chow fed 
(*) or 15-month chow fed (#). (f) Changes in fasting and fed blood glucose between chow fed young mice (3 months; white bars) old mice (15 months, gray bars) 
and metformin-fed old mice (15 months, black bars). Blood glucose measures were performed on a hand-held glucose meter using 10 µL of blood. Mice were 
tested fasting and 15 minutes after feeding. All data show the mean ± SD. n = 4 for all groups. (g) Body weight and lean mass comparisons between young mice 
(3 months; white bars) old mice (15 months, gray bars) and metformin-fed old mice (15 months, black bars). All data show the mean ± SD. n = 4 for all groups.
raw measurements of fenestrations (per drug treatment, per mouse) and analyzed using ImageJ software. (e) Representative SEM images following inhibitor 
pretreatment alone and following 50 µM metformin drug treatment. Scale bars show 1 µm. (f) Changes in porosity following 50 µM metformin treatment with 
and without pretreatment with L-NAME, Compound C or Peptide 18. Data are presented as a bar graph (mean ± SD), * indicates a p-value of < .05 compared 
to young control data. All statistics were performed using Kruskal–Wallis with post hoc Dunn’s test to compare between groups, n = 3 for all groups. All data 
were collected using 1,231–2,658 raw measurements of fenestrations (per drug treatment, per mouse) and analyzed using ImageJ software. (g) Cell viability 
as determined by MTT assays as per kit instructions following metformin, L-NAME, Compound C, Peptide 18 or Triton-X (negative control) treatments. Data 
shows mean ± SD with all experiments performed in triplicate. (h) dSTORM images show transgelin and actin cytoskeleton morphology changes promoted by 
metformin drug treatment in young and old mice. Images were produced following 40,000 image collections and processed using RapidSTORM software. Scale 
bar shown 5 µm, insert scale bar 1 µm. (i) Changes in transgelin densitometry relative to actin densitometry induced by metformin treatments in young and old 
mice. Data are presented as a bar graph (mean ± SD) with the percentage density of pixels per 1 µm2. Eight images were captured using a dSTORM microscope; 
data analysis was performed using Image J software. Images were converted to binary data with measurements taken across the whole cell. * indicates a 
p-value of < .05 compared to young control data; eight images per treatment group were analyzed.
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Figure 3. Effects of metformin treatment on SK-Hep1 cell lines. (a) Representative scanning electron microscopy images of SK-Hep1 cells following metformin 
treatment. Scale bar shows 1 or 5 µm. (b) Changes in p-AMPK, AMPK, p-eNOS, NOS, actin, and Ponceau protein expression as determined by western blot 
following metformin treatment. 107 cells were analyzed per sample. (c–d) Dose–response curves showing the % fold change for p-AMPK and AMPK (c), p-eNOS 
and NOS (d) (normalized to actin) with increasing metformin treatment. Data shows the mean ± SD based on three to four (technical replicates) individual 
experiments. * indicates a p-value of < .05, ** p < .01 compared to control data. Statistics were performed using Kruskal–Wallis with post hoc Dunn’s test to 
compare between groups. (e–g) Intracellular cGMP (e), ATP (f), and extracellular L-lactate (g) was determined by commercial assays. Dose–response curves 
are shown with changes in determinant relative to increasing metformin. Data shows the mean ± SD. Dotted line shows control (untreated) score. Intracellular 
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In Vivo Long-Term Studies in Mice
Three-month-old male C57/Bl6 mice (n  =  4 per treatment group) 
were obtained from the Animal Resource Centre in Perth, Western 
Australia and housed at the Charles Perkins Centre (The University 
of Sydney, NSW, Australia). Mice were group housed, maintained on 
a 12-hour light/dark cycle, 20–25°C, 50%–60% relative humidity 
and provided with bedding, ventilated caging systems, and enrich-
ment as per the ARRIVE guidelines. The metformin diet consisted of 
1 mg metformin per 1 g of standard chow (0.1%). Standard chow 
had the macronutrient ratio of 19:18:63 (protein: fat: carbohy-
drate). Food and water were given ad libitum with food usage and 
mouse weights monitored every third day. Mice either euthanized at 
3 months under anesthesia (xylazine 100 mg/kg ketamine, 10 mg/
kg) or maintained on either the metformin- or control chow-diets 
for 12 months prior to being euthanized under anesthesia (xylazine 
100 mg/kg ketamine, 10 mg/kg).
Insulin was measured using an ultra-sensitive mouse insulin 
ELISA kit according to the manufacturer’s instructions. Ten micro-
liters of blood were collected following fasting for 5 hours and fol-
lowing an oral bolus of 25% glucose solution from a tail vein snip/
collection. Euthanasia of mice was performed following blood col-
lection. SEM was performed on livers that had been fixed via portal 
vein perfusion as previous described (17–19).
Statistics
Statistical analyses between drug treatments experiments were per-
formed comparing multiple groups using Kruskal–Wallis tests with 
a post hoc Dunn’s method. A p-value of < .05 was deemed to be 
significant.
Results
Effects of Metformin on Isolated LSECs
LSECs from old mice had reduced fenestration porosity (young: 
5.11 ± 0.11%; old: 3.05 ± 0.10%; p = .001) and frequency (young: 
2.94 ± 0.10; old: 1.58 ± 0.11; p = .001) with no change in diameter 
(young: 143.54 ± 1.44 nm; old: 151.06 ± 5.70 nm; p =  .27) com-
pared to young mice (Figure 1a and d).
The effects of metformin on fenestrations in LSECs isolated from 
young and old mice are shown in Figure 1. In LSECs from both 
young and old mice, there was a dose-dependent increase in fenes-
tration porosity which was maximal at 50 µM metformin (Figure 1a 
and d) where porosity was increased by 25% in young mice (control: 
5.11 ± 0.11%; metformin: 6.44 ± 0.34%; p = .05) and by 50% in 
old mice (control: 3.05 ± 0.11%; metformin: 4.70 ± 0.28%; p = .04). 
This dosage of metformin also increased fenestration frequency 
(Figure 1a and d) in the same manner (20% in young mice [control: 
2.94 ± 0.10%; metformin: 3.53 ± 0.17%; p = .05]; 50% in old mice 
[control: 1.57 ± 0.10; metformin: 2.19 ± 0.15; p = .03]). Metformin 
did not alter fenestration diameter (Figure 1c).
The effect of metformin on fenestrations was reduced by pre-
treatment of LSECs with L-NAME, Compound C and Peptide 18 
(Figure 1e and f). Cell viability was not influenced by age, metformin, 
or any of the inhibitors (L-NAME, Compound C, Peptide 18; Figure 
1g). High dosages of metformin were associated with increased ex-
pression of transgelin in young mice only (p = .05; Figure 1h and i). 
Changes in the actin cytoskeleton were observed in LSECs from both 
young and old mice as evaluated by dSTORM (Figure 1h).
In Vivo Effects of Metformin
In vivo fenestration data demonstrated a similar age-related effect 
to isolated LSECs with reduced fenestration porosity (young 5.53 ± 
1.2%; old 3.47  ± 0.45%; p  =  .02) and frequency (young: 6.78  ± 
0.90; old: 4.67 ± 1.00; p =  .02) with no change in diameter com-
pared to young mice (Figure 2a and d). Mice fed 0.1% metformin 
for 12 months had a 30% increase in fenestration porosity (p = .02) 
and frequency (p = .05) compared to controls (Figure 2b and d). The 
use of 0.1% metformin diet reduced the age-related loss of fenestra-
tion porosity and frequency by 50%. These metformin-fed mice also 
demonstrated improvements in age-related changes in fasting and 
fed insulin levels (p < .05; Figure 2e). There were no differences in 
fasting or fed glucose levels; however, no age-related changes were 
observed (Figure 2f). There were no significant differences in body 
weight or lean mass (Figure 2g).
Effects of Metformin on SK-Hep1 Cells
SK-Hep1 cells developed fenestration-like structures following treat-
ment with 50  µM metformin (Figure 3a). Treatment with 50  µM 
metformin was associated with increases in p-AMPK (n = 4; p = .01), 
AMPK (n  =  4; p  =  .03), p-eNOS (n  =  4; p  =  .05), NOS (n  =  4; 
p = .04), cGMP (n = 3; p = .01), and ATP (n = 3; p = .05), which 
tended to be either dose-dependent or seen only at higher concentra-
tions depending upon the substrate (Figure 3b–f and i). Metformin 
did not influence L-lactate levels (n = 3; p = .67) (Figure 3g and i). 
Mitotracker green and TMRE studies showed that metformin in-
creased mitochondrial permeability potential (n = 3; p = .05; Figure 
3h and i) while dSTORM revealed reorganization of actin but no 
changes in transgelin (n = 8; p = .78; Figure 3i and f).
Discussion
Metformin increased fenestrations in LSECs. The effect of metformin 
was seen in LSECs isolated from young and old mice that were treated 
in vitro with metformin. This effect was also seen in the livers from 
older mice that had been fed 0.1% metformin for 12 months. In both 
cases, there was a 30% or greater increase in fenestration porosity and 
frequency. These results are consistent with a previous study where 
mice were fed 1% metformin every-other-week for 17 weeks then eu-
thanized at 24 months of age (20). In this study, we found that fenes-
tration porosity and frequency in vivo was increased by about 30% 
with metformin. Aging is associated with a reduction in fenestrations 
measurements were performed using 106 cells with 107 cells used for extracellular measurements were each experiment. Experiments were performed in 
triplicate. * indicates a p-value of < .05, ** p < .01, *** p < .001 compared to control data. Statistics were performed using Kruskal–Wallis with post hoc Dunn’s 
test to compare between groups. (h) Sample images of immunofluorescent staining for Mitotracker green and TMRE (red) were performed following metformin 
drug treatments in RMPI media without phenol red. Scale bar shows 25 µm. (i) Summary of changes induced by 50 µM metformin treatment on SK-Hep1 cells. 
Data represented as a bar graph with the mean ± SD. The % change in expression of p-AMPK, AMPK, p-eNOS, eNOS, cGMP, ATP, L-lactate, TMRE/Mitotracker 
green, and Transgelin/Actin are shown relative to control. Densitometry was performed on images acquired from confocal and dSTORM; eight images were 
captured with data analysis was performed using Image J software. Images were converted to binary data with measurements taken across the whole cell all 
other data was analysis as described in c–g. (f) dSTORM images show transgelin and actin cytoskeleton morphology changes promoted by metformin drug 
treatment in young mice. Images were produced following 40,000 image collections and processed using RapidSTORM software. Scale bar shown 5  µm.
Full color version is available within the online issue.







edgerontology/article/75/2/278/5518962 by guest on 11 January 2021
in LSECs, along with several other changes in the endothelium that 
have been termed “pseudocapillarization.” Metformin appears to be 
able to prevent age-related defenestration with chronic treatment, and 
reverse age-related defenestration with acute treatment.
Metformin is thought to influence aging via its effects on nutrient 
sensing pathways, particularly by activating AMPK. In this sense, 
it has been considered to be a calorie restriction-mimetic, that can 
replicate some of the beneficial effects of caloric restriction in ad 
libitum-fed animals. Therefore, it is of note that we have also found 
that caloric restriction prevents age-related defenestration and the 
other changes of pseudocapillarization (27). Metformin influences 
a broad range of age-related changes in animals (3,20,28) and there 
are now clinical trials planned to evaluate the effects of metformin 
on aging in humans (29). Our results indicate that the antiaging ef-
fects of metformin extend to the liver microvasculature. This has 
potential systemic implications. Fenestrations in LSECs provide a 
portal for the transfer of insulin and other substrates from the si-
nusoidal blood to the hepatocytes. In a previous study, we found 
that age-related loss of fenestrations directly contributed to hepatic 
insulin resistance and impaired insulin clearance in old mice and rats 
(14). By maintaining the patency of fenestrations, metformin would 
be expected to increase insulin clearance and the action of insulin 
on the liver. This is consistent with our finding that insulin levels 
were lower in mice on metformin and, of course, the well-established 
antidiabetic effects of metformin.
We also explored possible mechanistic pathways for the ef-
fects of metformin on fenestrations. In LSECs isolated from young 
mice, metformin increased fenestration porosity and frequency 
via a pathway that was dependent on pAMPK, eNOS/cGMP, and 
pMLCK/actin remodeling. We have highlighted in this study that 
all three of these pathways are required in regulating fenestrations 
following metformin treatment. These pathways are similar to those 
we and others have previously reported for several other agents that 
increase fenestrations in LSECs (19,30). We have previously re-
ported that actin disruption influences fenestrations (19). Here we 
identified that transgelin, a protein that inhibits the polymerization 
of actin (31), is upregulated in young but not old mice following 
metformin treatment. This represents a novel pathway for the regu-
lation of fenestrations and for the action of metformin. Lastly, 
metformin has been associated with lactic acidosis (32,33); there-
fore, we also investigated whether concentrations of 5–100  µM 
metformin had any impact on lactate production by the LSEC. 
There was no effect.
In this study, we examined the influence of metformin on 
SK-Hep1 cells which are an immortal human liver cell line with 
many characteristics of LSECs (34). Metformin was associated 
with the generation of fenestration-like structures and there was 
a concentration-dependent increase in p-AMPK, AMPK, and the 
ratio of p-AMPK/AMPK, consistent with the established effects 
of metformin on AMPK activation (6). We also demonstrated that 
metformin increased the expression of p-eNOS, NOS, and cGMP in 
SK-Hep1 cells. Metformin is usually considered to be an inhibitor 
of mitochondrial function leading to AMPK activation via reduced 
levels of ATP. However, we found that metformin was associated with 
a small increase in intracellular ATP levels. It should be noted that 
inhibition of mitochondrial function by metformin is concentration-
dependent and only has inhibitory effects at concentrations above 
1–5 mM (3,35), which is 10-fold greater than the highest concen-
trations we utilized. Moreover, low-dose metformin increased mito-
chondrial complex I activity in the livers of mice (3). Within LSECs, 
fenestrations are dependent upon actin remodeling, which requires 
ATP (36); therefore, any increase in ATP with metformin might pro-
mote fenestration formation. Furthermore, this result suggests that 
the effects of metformin on AMPK activation might not be entirely 
dependent upon decreased ATP levels, at least in SK-Hep1 cells. 
Further study is required to determine the changes in AMP relative 
to the increased ATP observed in this study.
We also demonstrated that metformin increased the expression of 
p-eNOS, NOS, and cGMP in SK-Hep1 cells. The production of nitric 
oxide is one of the other critical roles of LSECs that is reduced with 
age (see review by Maslak, Gregorius, Chlopicki (37)). Within the 
liver, nitric oxide is involved in the quiescence of hepatic stellate cells 
and regulation of hepatocytes (37). The restoration of a healthy LSEC 
phenotype (fenestrated and nitric oxide releasing) has been shown to 
prevent fibrosis progression and regression of fibrosis (38,39). This 
suggests that metformin via its actions on LSECs may be added to the 
beneficial effects of AMPK agonists for treating hepatic fibrosis (40).
It is important to note that there was a nonlinear concentration-
dependent effect of metformin on fenestrations in isolated LSECs: 
The effect was maximal at 50 µM and then decreased at 100 µM. 
The concentrations of metformin that have the greatest beneficial 
effects on hepatocytes is in the range of 0.1–10 mM (8), well above 
those we found to be beneficial for fenestrations in LSECs. The direct 
effects of metformin on molecular pathways within LSECs have not 
been previously reported. Dose-dependent aging effects have been 
seen in mice, with 0.1% dietary metformin causing increased life 
expectancy while 1% dietary metformin reduced lifespan (3). In our 
study, long-term administration of 0.1% metformin in the diet was 
associated with increased fenestrations and lower insulin levels, con-
sistent with the study showing that this dosage increases life span.
In conclusion, metformin was found to increase fenestration 
porosity and frequency in LSECs isolated from both young and old 
mice, via a pathway dependent on AMPK, NOS/cGMP, and MLCK/
actin remodeling in vitro. Long-term treatment with metformin in-
creased fenestrations in old mice which was associated with lower 
insulin levels. Along with its many other actions, metformin ameli-
orates age-related changes in the LSEC which might contribute to its 
effects on age-related insulin sensitivity.
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